The Latest Breaking News from Awakn Life Sciences Corp

Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding

Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has been granted funding for 66% of the costs from its phase 3 clinical trial  on 

Benzinga · Jul 20, 2022

UK To Fund Development Of Awakn's Ketamine-Assisted Therapy Program For Alcohol Use Disorder In US And UK

Biotech therapeutics company Awakn Life Sciences Corp.

Benzinga · Jul 5, 2022